2022
DOI: 10.1016/j.amsu.2022.104696
|View full text |Cite
|
Sign up to set email alerts
|

Primary spinal Non-Hodgkin Lymphoma presenting as impending cauda equina syndrome: A case report

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 19 publications
0
2
0
Order By: Relevance
“…To date, these questions remain unsolved, hindering the development of specific, let alone standard, recommendations. As the result, surgery, RT, and ICT are utilized randomly across a variety of the lymphoma types, grades, and stages, leading to indiscriminate sequencing of the different treatment options (Table 1) [5, 7, 8, 14‒45] and erratic and even contrasting clinical outcomes. Therefore, despite unequivocal benefits, the place of systemic therapy and even its necessity in a general treatment plan remains indeterminate.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…To date, these questions remain unsolved, hindering the development of specific, let alone standard, recommendations. As the result, surgery, RT, and ICT are utilized randomly across a variety of the lymphoma types, grades, and stages, leading to indiscriminate sequencing of the different treatment options (Table 1) [5, 7, 8, 14‒45] and erratic and even contrasting clinical outcomes. Therefore, despite unequivocal benefits, the place of systemic therapy and even its necessity in a general treatment plan remains indeterminate.…”
Section: Introductionmentioning
confidence: 99%
“…Surgery 2 → (immuno-) chemotherapy3 Perry et al[19] (1993), Khalid et al[23] (2004), Chang et al[7] (2013), Tang et al[24] (2013), Cho et al[25] (2015), Erol et al[26] (2016), Hashi et al[27] (2018), Adhikari et al[28] (2022), Ruiz and Garrido[29] (2023), Seok et al[30] (2023) 3 Surgery 2 → radiation → (immuno-) chemotherapy3 Friedman et al[14] (1976), Rathmell et al [18] (1992), Perry et al [19] (1993), Salvati et al [20] (1996), Monnard et al [21] (2006), Charfi et al [31] (2006), Peng et al [32] (2009), Tang et al [24] (2013), Hashi et al [27] (2018) 4 Surgery 2 → (immuno-) chemotherapy 3 → radiation Eeles et al [5] (1991), Fujino et al [33] (2002), Mally et al [34] (2011), Park et al [35] (2012), Wang et al [36] (2016), Msheik et al [37] (2023) 5 Radiation +/− steroids Mullins et al [38] (1971), Epelbaum et al [39] (1986), McDonald et al [40] (2000), Luo [41] (2005), Rades et al [8] (2016), Hashi et al [27] (2018) 6 Radiation → (immuno-) chemotherapy 3 Friedman et al [14] (1976), Epelbaum et al [39] (1986), Eeles et al [5] (1991), Tsukada et al [42] (1992), Fujino et al [33] (2002), Peng et al [32] (2009), Tang et al [24] (2013) 7 (Immuno-) chemotherapy 3 → radiation Wong et al [43] (1996), Vanneuville et al [44] (2000), McDonald et al [40] (2000), Wada et al [45] (2010), Hashi et al [27] (2018) 8 (Immuno-) chemotherapy 3 Epelbaum et al [39] (1986), Wong et al [43] (1996), Wada et al [45] (2010), Chang et al [7] (2013), Hashi et al [27] (2018)1The first authors' names and the year of publication provide a quick reference to corresponding treatment timelines 2. Indications for the surgery usually include an unknown diagnosis with or without myelopathy 3.…”
mentioning
confidence: 99%